{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000502","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.318095+00:00","generated_at":"2026-06-26T03:15:50.920890+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aldeyra CFO Joshua Reed resigns; Bruce Greenberg named interim CFO","bullets":["Joshua Reed resigns as CFO and Treasurer effective May 10, 2022, to pursue other opportunities.","Bruce Greenberg, current VP and Controller, appointed Interim CFO and Treasurer.","Greenberg has over 25 years of accounting experience; previously Corporate Controller at Karyopharm Therapeutics.","Reed will assist transition and participate in Aldeyra's Q1 2022 earnings call.","No disputes with management or board regarding Reed's resignation."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000502","json":"https://secwatch.observer/filing/0001157523-22-000502.json","markdown":"https://secwatch.observer/filing/0001157523-22-000502.md","text":"https://secwatch.observer/filing/0001157523-22-000502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000115752322000502/0001157523-22-000502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000115752322000502/a52701292.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:15:50.920890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a587446724","claim":"Joshua Reed resigned as Chief Financial Officer at Aldeyra Therapeutics, Inc..","evidence_excerpt":"On April 25, 2022, Joshua Reed notified Aldeyra Therapeutics, Inc. (the “Company”) of his intent to resign as the Company’s Chief Financial Officer and Treasurer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1341235/000115752322000502/0001157523-22-000502-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a8ca55956b","claim":"Bruce Greenberg was appointed as Interim Chief Financial Officer at Aldeyra Therapeutics, Inc..","evidence_excerpt":"Effective as of the Resignation Date, the Company plans to appoint Bruce Greenberg to serve as its Vice President of Finance, Interim Chief Financial Officer, and Treasurer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1341235/000115752322000502/0001157523-22-000502-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}